Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro

British Journal of Cancer

Volumn 77, Issue 2, 1998, Pages 216-220

  McGown, A T ^a   Jayson, G ^a   Pettit, G R ^b   Haran, M S ^a   Ward, T H ^a   Crowther, D ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Bryostatin; Protein kinase C; Synergy; Tamoxifen

Indexed keywords

ANTIESTROGEN; BRYOSTATIN 1; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; TAMOXIFEN;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; GROWTH INHIBITION; LEUKEMIA P 388; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

EID: 0031965131     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.36     Document Type: Article

References (20)

1. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Veno W, Wampler GL, Yeung KY, Alt D and Fryer JG (1993) Hormonal palization of chemoresistant ovarian cancer: three consecutive Phase II trials of the mid-Atlantic oncology program. J Clin Oncol 11: 1957-1968
2. Azzi A, Boscoboinik D and Henxey C (1992) The protein kinase family. Eur J Biochem 208: 547-557
3. Berkow RL and Kraft AS (1985) Bryostatin 1, a non-phorbol macro cyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun 131: 1109-1116
4. Dale IL and Gescher A (1989) Effects of activators of protein kinase C, including Bryostatins 1 and 2 on the growth of A549 human lung carcinoma cells. Int J Cancer 43: 158-163
5. Gescher A (1992) Towards selective pharmacological modulation of protein kinase C - opportunities for the development of novel anti-neoplastic agents. Br J Cancer 66: 10-19
6. Hennings H, Blumberg PM, Pettit GR, Herald CL, Shores R and Yuspa SH (1987) Bryostatin 1, an activator of protein kinase C, inhibits tumour promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 8: 1343-1346
7. Hocevar BA, Morrow DM, Tykocinski ML and Fields AP (1992) Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation. J Cell Science 101: 671-679
8. Hornung RL, Pearson JW, Beckwith M and Longo DL (1992) Preclinical evaluation bryostatin as an anticancer agent against several murine cell lines: in vitro versus in vivo activity. Cancer Res 52: 101-107
9. Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owens S and Pettit GR (1995) A Phase I trial of Bryoslatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 72: 461-468
10. Jetten AM, George MA, Pettit GR and Rearick JI (1989) Effects of Bryostatin 1 and retenoic acid on phorbol ester and diacylglycerol induced squamous differentiation in human tracheobronchial epithelial cells. Cancer Res 49: 3990-3995
11. Kennedy MJ, Prestigiocoms LJ, Tyler G, May WS and Davidson NE (1992) Differential effects of Bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res 52: 1278-1283
12. Levine B, May W, Tyler P and Hess A (1991) Response of JURKAT T cells to phorbol esters and Bryostatin 1: development of distinct functional responses and changes in protein kinase C activity. J Immunol 147: 3474-3481
13. O'Brian CA, Housey GM and Weinstein IB (1988) Specific and direct binding of protein kinase C to an immobilized Tamoxifen analogue. Cancer Res 48: 3626-3629
14. Pettit GR, Herald CL, Doubek DL and Herald DL (1982) Isolation and structure of Bryostatin 1. J Am Chem Soc 104: 6846-6848
15. Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F and Harris AL (1993) Phase I study of Bryostatin 1: assessment of interleukin-6 and tumour necrosis factor in vivo. J Natl Cancer Inst 85: 1812-1818
16. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown AT, Testa, N, Stern P, McDermott R, Potter M and Pettit GR (1993) A Phase I study of intravenous Bryostatin-1 in patients with advanced cancer. Br J Cancer 68: 418-424
17. Prendiville J, McGown AT, Gescher A, Dickson AJ, Courage C, Pettit GR, Crowther D and Fox BW (1994) Establishment of a murine leukaemia cell line resistant to the growth inhibitory effect of Bryostatin 1. Br J Cancer 70: 573-578
18. Steel GG and Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91
19. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A and Boyd MR (1991) Tetrazolium-based assay for cellular viability. A critical examination of selected parameters affecting formazan production. Cancer Res 51: 2515-2520
20. Yashuda I, Kishimato A, Tanaka S, Tominaga M, Sakurai A and Nishizuka Y (1990) A synthetic peptide for selective assay of protein kinase C. Biochem Biophys Res Commun 166: 1220-1225